NCT03385031View on ClinicalTrials.gov

Prospective Validation of 3D Dose Metrics as Selection Criteria for Adaptive Radiotherapy in Breast Cancer Patients

CompletedOBSERVATIONAL
Enrollment

46

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

August 20, 2018

Study Completion Date

August 20, 2018

Conditions
Breast Cancer
Interventions
OTHER

CBCT imaging

CBCT imaging at first and last fraction of radiotherapy treatment

Trial Locations (1)

6202 AZ

Maastricht Radiation Oncology, Maastricht

All Listed Sponsors
lead

Maastricht Radiation Oncology

OTHER

NCT03385031 - Prospective Validation of 3D Dose Metrics as Selection Criteria for Adaptive Radiotherapy in Breast Cancer Patients | Biotech Hunter | Biotech Hunter